Patient deaths prompted Memorial Sloan Kettering Cancer Center to briefly halt enrollment and update inclusion criteria for its CD19 directed chimeric antigen receptor T cell therapy. But partner Juno Therapeutics Inc. and other CAR players don't think this will affect development of similar therapies.

Adoptive cell therapies are widely seen as the next great advance in the treatment of cancer.